Project BMS CA209-498 – A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with…

Basic data

Acronym:
BMS CA209-498
Title:
A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma
Duration:
15/04/2016 to 14/04/2019
Abstract / short description:
A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma
Keywords:
clinical trial
klinische Studie

Involved staff

Managers

Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Diagnostic and Interventional Neuroradiology
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine
Help

will be deleted permanently. This cannot be undone.